title: Tumor necrosis factor inhibition and adipose tissue distribution -- are reported changes relevant to cardiometabolic risk?
authors.affiliation: Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8 sheaneb@yahoo.com.
authors.forename: Barry J
authors.initials: BJ
authors.lastname: Sheane
mesh_terms: D050153:Abdominal Fat / Q000187:drug effects*; D050154:Adiposity / Q000187:drug effects*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D018501:Antirheumatic Agents / Q000494:pharmacology*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology*; D000069285:Infliximab; D008297:Male; D018124:Receptors, Tumor Necrosis Factor; D025241:Spondylarthritis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept